GPC Prostate Drug Needs More Data, FDA Panel Says

U.S. regulators should wait for final survival data before deciding whether to approve
GPC Biotech's proposed prostate cancer pill Orplatna, an advisory panel said on Tuesday in a 12-0 vote.

The Food and Drug Administration usually follows panel recommendations. The agency is expected to make a final decision on whether to clear Orplatna by mid-August.

Contact Health Care


    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More